First patient screened in phase 3b trial of IOP-lowering eye drop
Nicox announced that the first patient has been screened in its Whistler phase 3b clinical trial of NCX 470, a nitric oxide-donating bimatoprost eye drop designed to lower IOP in patients with open-angle glaucoma or ocular hypertension.
According to a company press release, the double-masked, placebo-controlled trial will enroll approximately 20 healthy individuals with ocular hypertension and investigate trabecular meshwork overflow and episcleral venous pressure, among other parameters. The trial is expected to be completed in 1 year.
“The data from this trial is expected to provide further evidence of the dual mechanism of action of NCX 470, as we should be able to tease out parameters related to how the nitric oxide and the prostaglandin analog components of NCX 470 function,” Doug Hubatsch, executive vice president and chief scientific officer at Nicox, said in the release.
Results from the Mont Blanc phase 3 trial, which were announced in October 2022, and the ongoing Denali phase 3 trial, will support new drug application submissions for NCX 470 in the U.S. and China, the company stated.
Read more about